Clinical Trial: 20423

Trial Status: Open
Disease Type: Lung
Trial ID 20423
Sponsor ID eFT508-0011

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination with Anti-PD-(L)1 Therapy in Subjects with NSCLC as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy

Principal Investigator
Timothy A. McCarthy, MD
5 Locations


Fairfax Office

Gainesville Office

Arlington Office

Alexandria Office

Loudoun Office

Learn More About This Trial
Other Relevant Trials
Trial ID TAK-981-1502
Sponsor ID Takeda Oncology

Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors

1 Location
Trial ID M20-111
Sponsor ID AbbVie

“A Phase 1 first in human study evaluating safety and efficacy of ABBV-637 as either monotherapy or in combination in adult subjects with relapsed and refractory solid tumors”

1 Location